Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Price, News & Analysis

Liminal BioSciences logo

About Liminal BioSciences Stock (NASDAQ:LMNL)

Key Stats

Today's Range
$8.48
$8.50
50-Day Range
$8.38
$8.50
52-Week Range
$3.10
$8.50
Volume
5,000 shs
Average Volume
63,470 shs
Market Capitalization
$26.35 million
P/E Ratio
29.31
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Receive LMNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

LMNL Stock News Headlines

Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
See More Headlines

LMNL Stock Analysis - Frequently Asked Questions

Liminal BioSciences Inc. (NASDAQ:LMNL) issued its earnings results on Monday, November, 15th. The company reported $27.40 EPS for the quarter, beating the consensus estimate of ($2.80) by $30.20. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.02 million. Liminal BioSciences had a negative trailing twelve-month return on equity of 88.44% and a net margin of 248.35%.

Liminal BioSciences's stock reverse split on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Liminal BioSciences investors own include Corbus Pharmaceuticals (CRBP), Bionano Genomics (BNGO), HubSpot (HUBS), iBio (IBIO), Dynavax Technologies (DVAX), Diamondback Energy (FANG) and NIO (NIO).

Company Calendar

Last Earnings
11/15/2021
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMNL
Employees
251
Year Founded
N/A

Profitability

Net Income
$380,000.00
Pretax Margin
-5,729.40%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$8.97 per share

Miscellaneous

Free Float
3,036,000
Market Cap
$26.35 million
Optionable
Not Optionable
Beta
1.03
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LMNL) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners